Thermo Fisher Scientific
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer.
Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them.
Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.
Stock Symbol: TMO
1679 articles about Thermo Fisher Scientific
-
Thermo Fisher Scientific to Present at 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024
1/3/2024
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 11:15 a.m. (EST).
-
Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, January 31, 2024
1/2/2024
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the fourth quarter and full year 2023 before the market opens on Wednesday, January 31, 2024, and will hold a conference call on the same day at 8:30 a.m. EST.
-
Thermo Fisher Scientific Announces Launch of Innovative CorEvitas Pharmacovigilance Platform for Clinical Research Registries
12/20/2023
Thermo Fisher Scientific Inc. today announced the launch of CorEvidence, a proprietary cloud-based data lake platform optimizing pharmacovigilance case processing and safety data management processes.
-
Thermo Fisher Scientific Introduces New Sample Preparation Solutions to Simplify and Automate Respiratory Diagnostic Testing
12/11/2023
New Thermo Scientific KingFisher Apex Dx system and Applied Biosystems MagMAX Dx Isolation Kit improve preanalytical workflows for clinical laboratories.
-
Thermo Fisher Scientific and Project HOPE Partner to Advance Health Equity Among HIV Positive Youth in Sub-Saharan Africa
12/1/2023
Thermo Fisher Scientific Inc. and Project HOPE today announced a new partnership to improve the wellbeing and treatment outcomes of adolescents and young persons living with HIV in Nigeria.
-
Thermo Fisher Scientific Extends the Expiration of Tender Offer for All Outstanding Common Shares and ADSs of Olink
12/1/2023
Thermo Fisher Scientific Extends the Expiration of Tender Offer for All Outstanding Common Shares and ADSs of Olink.
-
Thermo Fisher Scientific & Flagship Pioneering Expand Ongoing Strategic Partnership to Jointly Create New Platform Companies with First-in-Class Enabling Technologies for Life Sciences
11/28/2023
Thermo Fisher Scientific Inc., the world leader in serving science, and Flagship Pioneering, the bioplatform innovation company, announced the formation of a strategic partnership to develop and commercially scale multiproduct platforms on an accelerated basis.
-
Thermo Fisher Scientific Authorizes $4 Billion of Share Repurchases - November 14, 2023
11/14/2023
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors has authorized the repurchase of $4 billion of shares of its common stock in the open market or in negotiated transactions.
-
Thermo Fisher Scientific Declares Quarterly Dividend - November 09, 2023
11/9/2023
Thermo Fisher Scientific Inc., the world leader in serving science, announced that its Board of Directors authorized a quarterly cash dividend of $0.35 per common share, payable on January 16, 2024, to shareholders of record as of December 15, 2023.
-
Thermo Fisher Scientific Commences Tender Offer for All Outstanding Common Shares and ADSs of Olink
10/31/2023
Thermo Fisher Scientific Inc. and Olink Holding AB announced that Thermo Fisher has commenced the previously announced tender offer through a direct, wholly owned subsidiary of Thermo Fisher to acquire all of the outstanding common shares and all of the outstanding American Depositary Shares of Olink for $26.00 per common share and per ADS, in cash.
-
Thermo Fisher Scientific Reports Third Quarter 2023 Results
10/25/2023
Thermo Fisher Scientific Inc., the world leader in serving science, reported its financial results for the third quarter ended September 30, 2023.
-
Thermo Fisher Scientific Signs Companion Diagnostic Agreement with Boehringer Ingelheim to Select Patients with NSCLC for Targeted Therapy Treatment
10/19/2023
To support emerging precision therapies and improve patient outcomes by increasing access to reliable genomic testing needed to match patients with targeted cancer treatments, Thermo Fisher Scientific today announced a companion diagnostic (CDx) partnership with Boehringer Ingelheim.
-
Thermo Fisher Scientific to Acquire Olink, a Leader in Next-Generation Proteomics
10/17/2023
Thermo Fisher Scientific Inc. and Olink Holding AB announced that their respective boards of directors have approved Thermo Fisher’s proposal to acquire Olink for $26.00 per common share in cash, representing $26.00 per American Depositary Share in cash.
-
Multiply Labs Collaborates with Industry Leaders University of California San Francisco, Cytiva, Thermo Fisher Scientific and Charles River to Deliver a Successful Proof-of-Concept of Robotic Cell Therapy Manufacturing
10/11/2023
Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, announced that its proof-of-concept robotic system, developed along with UCSF, Cytiva, Thermo Fisher Scientific and Charles River, has been successfully completed.
-
Thermo Fisher Scientific Expands St. Louis Manufacturing for Complex Biologic Treatments
10/5/2023
Thermo Fisher Scientific, the world leader in serving science, today expanded its manufacturing capacity in St. Louis to support biologic therapies for diseases ranging from cancers to auto immune conditions to rare genetic disorders.
-
Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 25, 2023
10/3/2023
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the third quarter 2023 before the market opens on Wednesday, October 25, 2023, and will hold a conference call on the same day at 8:30 a.m. EDT.
-
Devyser and Thermo Fisher Scientific collaborate to promote laboratory services to advance pharmaceutical research
9/13/2023
Devyser and Thermo Fisher Scientific have entered into a collaboration agreement to promote laboratory services.
-
Thermo Fisher Scientific Recognized by R&D 100 Awards for Innovations in Science and Technology
9/8/2023
Thermo Fisher Scientific Inc., the world leader in serving science, has been recognized by the R&D 100 Awards, honoring the top 100 revolutionary products in science and technology from around the world, for three unique innovations that aid researchers’ and scientists’ work in a variety of life science applications, including bioproduction and small-molecule analysis.
-
Thermo Fisher Scientific and National Minority Quality Forum Collaborate to Make Clinical Research More Accessible to Historically Underserved Communities
9/7/2023
Thermo Fisher Scientific Inc., the world leader in serving science, and the National Minority Quality Forum, an independent not-for-profit research and education organization, announced a collaboration to help bring clinical research to historically underserved patient populations through NMQF’s Alliance for Representative Clinical Trials.
-
Thermo Fisher Scientific Helps Accelerate Cell Therapy Manufacturing with a Next-Generation Platform of Gibco™ CTS™ Detachable Dynabeads™
9/6/2023
Thermo Fisher Scientific Inc., the world leader in serving science, today announced the Gibco CTS Detachable Dynabeads (CTS Detachable Dynabeads)*, its next-generation platform of Dynabeads with the first active release mechanism of its kind for clinical trial and commercial manufacturing use.